Sofie Joris

600 total citations
12 papers, 94 citations indexed

About

Sofie Joris is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Sofie Joris has authored 12 papers receiving a total of 94 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Genetics and 3 papers in Molecular Biology. Recurrent topics in Sofie Joris's work include BRCA gene mutations in cancer (6 papers), PARP inhibition in cancer therapy (5 papers) and DNA Repair Mechanisms (3 papers). Sofie Joris is often cited by papers focused on BRCA gene mutations in cancer (6 papers), PARP inhibition in cancer therapy (5 papers) and DNA Repair Mechanisms (3 papers). Sofie Joris collaborates with scholars based in Belgium, Netherlands and United States. Sofie Joris's co-authors include Jacques De Grève, Sylvia De Brakeleer, Erik Teugels, Lore Decoster, Christel Fontaine, Christos Sotiriou, Martine Piccart, M Bonduelle, Christine Desmedt and Marian Vanhoeij and has published in prestigious journals such as Annals of Oncology, BMC Cancer and Acta Oncologica.

In The Last Decade

Sofie Joris

9 papers receiving 91 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sofie Joris Belgium 6 47 47 37 27 17 12 94
Carolina Velázquez France 6 47 1.0× 26 0.6× 28 0.8× 25 0.9× 22 1.3× 10 82
Paula Rofes Spain 6 65 1.4× 30 0.6× 52 1.4× 35 1.3× 48 2.8× 11 118
Kelly McGoldrick United States 6 67 1.4× 51 1.1× 61 1.6× 39 1.4× 11 0.6× 10 122
Sasi Arunachalam United States 6 48 1.0× 19 0.4× 25 0.7× 25 0.9× 9 0.5× 11 93
Ulrike Faust Germany 5 47 1.0× 16 0.3× 45 1.2× 26 1.0× 19 1.1× 13 83
Sheng Yu United Kingdom 6 78 1.7× 24 0.5× 16 0.4× 25 0.9× 15 0.9× 9 118
Clara Esteban-Jurado Spain 4 45 1.0× 31 0.7× 31 0.8× 23 0.9× 51 3.0× 6 87
Youstina Hanna Canada 3 36 0.8× 39 0.8× 12 0.3× 36 1.3× 13 0.8× 3 88
Christine Lasset France 3 70 1.5× 55 1.2× 46 1.2× 64 2.4× 50 2.9× 3 132
Kai‐Keen Shiu United Kingdom 3 41 0.9× 45 1.0× 20 0.5× 58 2.1× 26 1.5× 3 95

Countries citing papers authored by Sofie Joris

Since Specialization
Citations

This map shows the geographic impact of Sofie Joris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sofie Joris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sofie Joris more than expected).

Fields of papers citing papers by Sofie Joris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sofie Joris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sofie Joris. The network helps show where Sofie Joris may publish in the future.

Co-authorship network of co-authors of Sofie Joris

This figure shows the co-authorship network connecting the top 25 collaborators of Sofie Joris. A scholar is included among the top collaborators of Sofie Joris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sofie Joris. Sofie Joris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Joris, Sofie, Philippe Giron, Catharina Olsen, et al.. (2024). Identification of RAD17 as a candidate cancer predisposition gene in families with histories of pancreatic and breast cancers. BMC Cancer. 24(1). 723–723. 1 indexed citations
3.
Joris, Sofie, Hannelore Denys, Joëlle Collignon, et al.. (2023). Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study. ESMO Open. 8(6). 102041–102041. 18 indexed citations
4.
5.
Decoster, Lore, Philippe Aftimos, Sylvie Rottey, et al.. (2023). 201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study. Annals of Oncology. 34. S262–S262. 1 indexed citations
6.
Joris, Sofie, Christel Fontaine, Lore Decoster, et al.. (2022). Efficacy of a Flat Low Dose of Nivolumab in Advanced Cancer: A Retrospective Case Series. Anticancer Research. 42(3). 1433–1437. 6 indexed citations
7.
Joris, Sofie, Hannelore Denys, Daphné t’Kint de Roodenbeke, et al.. (2021). 88P Efficacy of olaparib in advanced cancers occurring in patients with germline or somatic tumor mutations in homologous recombination (HR) genes, a Belgian Precision phase II basket study. Annals of Oncology. 32. S394–S394. 1 indexed citations
8.
Xavier, Catarina, Johannes Heemskerk, Nick Devoogdt, et al.. (2020). 68GaNOTA-anti-MMR-Nb for PET/CT assessment of protumorigenic macrophages in patients with solid tumors: preliminary results of a phase I clinical trial. 1 indexed citations
9.
Brakeleer, Sylvia De, M Bonduelle, Sofie Joris, et al.. (2019). Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families. BMC Cancer. 19(1). 313–313. 30 indexed citations
10.
11.
Joris, Sofie, Thierry Pieters, Anne Sibille, et al.. (2019). Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program. Journal of Geriatric Oncology. 11(5). 796–801. 9 indexed citations
12.
Brakeleer, Sylvia De, Jacques De Grève, Christine Desmedt, et al.. (2015). Frequent incidence of BARD1‐truncating mutations in germline DNA from triple‐negative breast cancer patients. Clinical Genetics. 89(3). 336–340. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carolina Velázquez Breakdown of academic impact, for papers by Paula Rofes Breakdown of academic impact, for papers by Kelly McGoldrick Breakdown of academic impact, for papers by Sasi Arunachalam Breakdown of academic impact, for papers by Ulrike Faust Breakdown of academic impact, for papers by Sheng Yu Breakdown of academic impact, for papers by Clara Esteban-Jurado Breakdown of academic impact, for papers by Youstina Hanna Breakdown of academic impact, for papers by Christine Lasset Breakdown of academic impact, for papers by Kai‐Keen Shiu
Rankless by CCL
2026